Next Phase Newsletter

A private investment firm based in Florida is currently making investments from its second fund, which is specifically focused on early commercialization stage medical device companies with at least one product on the market and in need of funding to grow sales and broaden their product offering. The firm seeks to allocate $250K to $3M (in equity or mezzanine) per company. The firm invests in companies that are based in the USA.

The firm seeks to invest in medical devices that provide solutions to unmet orthopedic, neurosurgical, and gastroenterology problems. The firm prefers Class I and II devices that are nearing or have regulatory approval.

The company must have at least one product on the market to be considered.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A multi-family office based in Canada has historically focused on the mining, oil and gas industries, but is beginning to become more involved with direct investments in the early stage healthcare space. Initial investments can range from $500k – $5M, but has a large network of family offices that they may syndicate with on larger deals. The group is flexible in terms of financing structures, and is open to straight equity in priced financing rounds as well as convertible notes, depending on the stage and specifics of the deal. The group has the capability to lead, but has no preference and will also co-invest as a syndicate, and is focused on companies in the U.S. and Canada.

The group is fairly new to the healthcare space and is primarily focused on the medtech and healthcare IT sectors, and is open to a variety of technologies/companies in these areas. The group has a specific interest in AI/big data applications in healthcare, and the primary screening criteria for all prospective companies being that the company have a very scalable business model. Further, the group looks for companies that have exhibited some sort of traction or customer support. In the medtech space, the group will look at medical devices pre-FDA approval on a secondary basis.

The group invests in companies in North America, but has no strict requirements for companies or management teams. The group does not require a board seat along with an investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A single-family office organization based in California is generally looking to make Seed and Series A investments in emerging life science companies. The firm can make investments ranging for $100,000 to $2 million and is currently interested in companies based throughout the US.

The firm is looking for companies in sectors of therapeutics, diagnostics and medical devices. The firm is generally open to all indications but has increased interests in ophthalmology and dermatology. The firm is focused on pre-clinical stage companies and is comfortable working with early university spinouts.

The firm is looking for privately held companies. The firm is open to working with firms that have incomplete management teams and has experience in helping form a team around an idea. The firm also has relationships with a CRO and can offer additional strategic value in addition to capital.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A Boston-based venture firm specializes in early stage opportunities in med-tech, diagnostics, and instruments. Currently, the firm has a total AUM of $125 million. Typically, the firm initially invests in a start-up at the early stage, but reserves capital for participation later on. The firm typically makes a first investment in the range of $1-3 million, but is open to making larger or smaller allocations as opportunities arise. The firm expects to invest a total in the range of $7-12 million in a given portfolio company as it makes progress toward a successful exit. The firm prefers to act as a lead investor for early stage deals.

The firm is most interested in companies developing Medical devices, Diagnostics tools and Instrumentation. The firm is looking for companies targeting global unmet clinical needs in areas such as oncology, cardiovascular disease, obesity, and women’s health. The firm is willing to invest in companies that are pre-prototype as well as those that have a working prototype of their product.

The firm looks to act as a long term strategic partner with its portfolio companies. The firm looks for experienced management teams and generally looks to take a board seat into companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A non-profit foundation is dedicated to accelerating the adoption of focused ultrasound to be used with therapeutic treatments. The foundation provides funding in the form of non-dilutive research grants as well as equity investments within early stage technologies that utilize focused ultrasound within their therapies. Examples include the use of focused ultrasound as a drug delivery mechanism. The foundation invests globally and focuses can invest anywhere between $100 thousand USD and a couple million to get early stage focused ultrasound using therapeutics to the proof of concept stage. The foundation invests globally.

The foundation is interested in technologies that utilize focused ultrasound and can aid in the adoption of this technology as a standard in the therapeutics world. This includes the use of focused ultrasound as a drug delivery mechanism, as part of a therapy (non-invasive thermal ablation), etc. Within these sectors, the firm is particularly interested in neurological indications, cancer indications, immunotherapies, and pediatric indications. The firm currently focuses on pre-clinical and phase I assets, but is also willing to invest in phase II assets that are nearing a significant milestone.

The foundation is looking for a team that is capable of taking the technology to a proof of concept stage as their main goal while investing is to accelerate the adoption of ultrasound for use in therapeutics.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A fully integrated pharmaceutical business that launched as a wholly-owned subsidiary of a large South Korea-based corporate is actively engaging in partnering with early-stage companies. The corporate is one of the largest conglomerates in South Korea, and a well-established leader in the food, feed, and biotech industry. Historically, the firm has had a successful track record of commercializing new drugs. The firm is actively seeking in-licensing and collaborative opportunities to add to their growing pipeline that covers areas of high, unmet medical need. The firm will seek opportunities globally.

The firm is currently seeking early-stage, in-licensing opportunities with strongest interest in antibodies and cell/gene therapies in nonalcoholic steatohepatitis (NASH) or immuno-oncology.

The firm is seeking to partner with early-stage companies developing novel therapeutics with management teams of strong scientific background and expertise.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm with main offices in Shanghai, China is currently managing two angel funds. On average, the initial size of investment is in the $1-6M range, but the firm has the capacity to invest more in companies they identify as a strong fit. The firm has 5 innovation centers across China focusing on different special areas in Life Sciences and Healthcare. With over 8 years operating experience of international medical technology incubators, the firm looks to tailor its services to help portfolio companies reaching key value-added milestones. The firm will consider opportunities based in China and around the globe, companies within a strong China angle involvement is their sweet spot. The firm is actively seeking distribution rights and new investment opportunities.

The firm is a flexible and opportunistic investor that is currently considering Therapeutics, Medical Devices, Diagnostics, Healthcare IT, and Biotechnology R&D Services. The firm is opportunistic in terms of subsector and indication and is willing to consider companies targeting orphan indications. The firm is open to novel medical devices of all FDA regulatory pathways, including 510k and PMA. In terms of therapeutics, the firm will look at products in pre-clinical stages. Regarding medical devices and diagnostics, the firm will invest at any stage of development.

The firm will invest in privately held companies only, and the firm can participate as either lead or co-investor. The firm has no specific requirements for the management team. Team members who speak Mandarin may be a plus but is not required. The firm may take a board seat in applicable cases.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.